Metallothionein-I/II double knockout mice are hypersensitive to lead-induced kidney carcinogenesis: Role of inclusion body formation

• Published in: Cancer research (Chicago, Ill.) Vol. 64; no. 21; pp. 7766 - 7772
• Main Authors: WAALKES, Michael P, JIE LIU, GOYER, Robert A, DIWAN, Bhalchandra A
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01-11-2004
• Subjects: Animals; Antineoplastic agents; Biological and medical sciences; Body Weight; Inclusion Bodies - physiology; Kidney - pathology; Kidney - ultrastructure; Kidney Neoplasms - chemically induced; Kidney Neoplasms - mortality; Kidney Neoplasms - pathology; Lead - toxicity; Medical sciences; Metallothionein - physiology; Mice; Mice, Knockout; Pharmacology. Drug treatments; Tumors; Urinary system; Animal; Knockout mouse; Activity; Inclusion body; Carcinogenesis; Metallothionein; Kidney
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-04-2220

Lead is an environmental nephrotoxicant and probable human carcinogen. Elucidating factors predisposing populations to lead toxicity is an important public health issue. Recently, we found that metallothionein-I/-II double knockout (metallothionein-null) mice that are unable to produce the major forms of metallothionein do not produce lead inclusion bodies, which are thought to mitigate lead toxicity, and were sensitive to the subchronic toxic effects of lead exposure (10 weeks), showing modestly diminished renal function and nephromegaly compared with wild-type (WT) mice. It is unclear how this knockout might impact lead carcinogenesis. Thus, the effects of lead(II) acetate were tested in groups (n = 25) of male metallothionein-null and WT mice receiving drinking water with 0, 1,000, 2,000, or 4,000 parts per million lead for up to 104 weeks. Renal proliferative lesions (adenoma and cystic tubular atypical hyperplasia) were much more common and more severe in lead-exposed metallothionein-null mice than in WT mice. A metastatic renal cell carcinoma also occurred in a lead-treated metallothionein-null mouse, whereas none occurred in WT mice. Lead-induced renal proliferative lesions showed marked overexpression of cyclin D1, a common feature of human renal tumors. Renal lead-containing nuclear inclusion bodies were frequently observed in WT mice but did not form in metallothionein-null mice. Metallothionein was often found associated with the outer portion of these inclusion bodies. Thus, the metallothionein-null mice cannot form renal inclusion bodies, even after protracted lead exposure, and this increases the carcinogenic potential of lead. Poor production of metallothionein may predispose human populations to lead carcinogenicity.